Camilleri Michael, Saito Yuri A
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Methods Mol Biol. 2008;448:395-412. doi: 10.1007/978-1-59745-205-2_13.
It is anticipated that unraveling the human genome will have a direct impact on the management of specific diseases. Variations or mutations in genes involved in drug metabolism or disease pathophysiology in gastroenterology and hepatology are expected to have effect on response to therapy. The spectrum of diseases is vast. Thus, we focus this review on clinical pharmacogenetics of inflammatory bowel disease, Helicobacter pylori infections, gastroesophageal reflux disease, irritable bowel syndrome, liver transplantation, and colon cancer. Although only a few genotyping tests are used regularly in clinical practice, we anticipate that in the future there will be more routine use of many of the tests described in this review.
预计解开人类基因组将对特定疾病的管理产生直接影响。胃肠病学和肝病学中涉及药物代谢或疾病病理生理学的基因变异或突变预计会对治疗反应产生影响。疾病的范围很广。因此，本综述将重点关注炎症性肠病、幽门螺杆菌感染、胃食管反流病、肠易激综合征、肝移植和结肠癌的临床药物遗传学。虽然临床实践中目前仅定期使用少数基因分型检测，但我们预计未来本综述中描述的许多检测将得到更常规的应用。
